Welcome to our dedicated page for Rocket Pharmaceu news (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceu stock.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company developing investigational genetic therapies for rare and often life-threatening disorders. The RCKT news feed on Stock Titan aggregates company announcements, press releases and third-party coverage related to its AAV and lentiviral gene therapy programs.
Investors following Rocket’s news can track updates on its adeno-associated viral (AAV) cardiovascular portfolio, which includes RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM) and RP-A701 for BAG3-associated dilated cardiomyopathy (BAG3-DCM). News items frequently cover clinical trial milestones, such as FDA lifting a clinical hold on the pivotal Phase 2 trial of RP-A501, preliminary Phase 1 data for RP-A601, and IND clearance and Fast Track designation for RP-A701.
The news stream also highlights developments in Rocket’s lentiviral (LV) hematology portfolio, including regulatory progress for KRESLADI (marnetegragene autotemcel; marne-cel) in severe leukocyte adhesion deficiency-I (LAD-I). Articles may discuss FDA acceptance of the resubmitted Biologics License Application (BLA), the setting of a Prescription Drug User Fee Act (PDUFA) target action date, and clinical data showing survival and infection outcomes in treated patients.
Beyond pipeline updates, RCKT news includes financial results, strategic corporate reorganization and pipeline prioritization announcements, leadership and board changes, equity inducement grants and participation in major healthcare investor conferences. By reviewing this page regularly, readers can follow how Rocket’s clinical, regulatory and corporate events may influence sentiment around RCKT stock and gain context on the company’s progress in gene therapy for rare cardiovascular and hematologic diseases.
Rocket Pharmaceuticals (NASDAQ: RCKT) has announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to its investigational gene therapy RP-L201 for treating Leukocyte Adhesion Deficiency-I (LAD-I). This designation is based on encouraging safety and efficacy data from the ongoing Phase 1/2 trial. The company aims to expedite the delivery of this potentially curative therapy for pediatric patients suffering from severe LAD-I, with initial Phase 2 trial data expected in Q2 2021.
Rocket Pharmaceuticals announces promising preliminary results from its Phase 1 trial of RP-L301 for treating Pyruvate Kinase Deficiency (PKD). The therapy demonstrated durable normalization of hemoglobin levels for up to 6 months, with patient L301-006-1001 showing an increase from ~7.4 g/dL to 13.9 g/dL and significant bilirubin improvement. RP-L301 was well tolerated, with no serious safety issues reported. The company is set to present more comprehensive data at a scientific venue later this year, affirming the therapy's potential in addressing PKD's substantial burden.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced that its investigational gene therapy, RP-L201, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. This designation, granted based on promising safety and efficacy data from an ongoing Phase 1/2 clinical trial, allows for expedited development of the therapy aimed at treating Leukocyte Adhesion Deficiency-I (LAD-I). Patient enrollment for the trial is complete, providing optimism for future FDA dialogue and potential registration. The company plans to share trial data in the second quarter of 2021.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported strong operational results for 2020, boasting a cash position of $482.7 million, sufficient to fund operations into H2 2023. The company anticipates significant clinical advancements in 2021, including data from its five gene therapy programs. Positive updates were noted in trials for Danon Disease, Fanconi Anemia, and Leukocyte Adhesion Deficiency-I. Notably, Rocket strengthened its balance sheet through a $300 million equity offering and leadership expansion. The FDA granted Fast Track Designation for key programs, highlighting the potential for expedited product development.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company, is participating in two upcoming healthcare conferences. Gaurav Shah, M.D., CEO, will engage in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 2:20 p.m. ET. The company will also attend the Cowen’s 41st Annual Health Care Conference on March 2, 2021. A live audio webcast of the events will be accessible on the company’s website, with a replay available post-conference.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced plans to establish a new R&D and CMC facility in Cranbury, New Jersey, expanding its capabilities for genetic therapies targeting rare childhood disorders. The 103,720 ft2 facility aims to enhance clinical development and is backed by a recent capital raise of approximately $300 million, extending Rocket's cash runway into the second half of 2023. The facility will support cGMP production and R&D, focusing on advancing five gene therapies, with significant data expected this year.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced that CEO Gaurav Shah will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:50 p.m. ET. The presentation will focus on the company's clinical-stage pipeline of genetic therapies targeting rare childhood disorders, including Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and others. A live audio webcast will be available on Rocket's investor website, with a replay accessible post-conference.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has announced the pricing of a public offering of 4,642,858 shares of its common stock at $56.00 per share, aiming to raise approximately $260 million before expenses. The offering, set to close around December 14, 2020, will fund the development of gene therapies for rare diseases, including filing for market authorization for RP-L201 in the U.S. and Europe. The underwriters also hold a 30-day option to purchase an additional 696,428 shares.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has initiated an underwritten public offering of $175 million of its common stock, with an option for underwriters to purchase an additional 15%. The funds will be allocated to advancing gene therapies for rare diseases, including the marketing authorization for RP-L201, enhancing manufacturing capabilities, and general corporate purposes. The offering is contingent on market conditions and follows an effective shelf registration statement with the SEC.
Rocket Pharmaceuticals (NASDAQ: RCKT) has released preliminary data from its Phase 1 clinical trial of RP-A501, a gene therapy targeting Danon Disease. The therapy was well tolerated in the low dose cohort, showing early signs of clinical benefit, including increased gene expression and improved biomarkers for cardiac function. The trial reported manageable safety profiles, with no severe adverse events noted. Additionally, the preliminary results indicate potential for RP-A501 to offer significant therapeutic benefits for patients suffering from this rare genetic disorder.